JP2018506507A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506507A5 JP2018506507A5 JP2017528491A JP2017528491A JP2018506507A5 JP 2018506507 A5 JP2018506507 A5 JP 2018506507A5 JP 2017528491 A JP2017528491 A JP 2017528491A JP 2017528491 A JP2017528491 A JP 2017528491A JP 2018506507 A5 JP2018506507 A5 JP 2018506507A5
- Authority
- JP
- Japan
- Prior art keywords
- xaa
- chem
- prevention
- treatment
- prelinker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14195172 | 2014-11-27 | ||
| EP14195172.3 | 2014-11-27 | ||
| PCT/EP2015/077757 WO2016083499A1 (en) | 2014-11-27 | 2015-11-26 | Glp-1 derivatives and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506507A JP2018506507A (ja) | 2018-03-08 |
| JP2018506507A5 true JP2018506507A5 (OSRAM) | 2019-01-10 |
| JP6730278B2 JP6730278B2 (ja) | 2020-07-29 |
Family
ID=51982467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017528491A Active JP6730278B2 (ja) | 2014-11-27 | 2015-11-26 | Ｇｌｐ−１誘導体及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11572398B2 (OSRAM) |
| EP (1) | EP3226906B1 (OSRAM) |
| JP (1) | JP6730278B2 (OSRAM) |
| CN (1) | CN106999602B (OSRAM) |
| ES (1) | ES2739289T3 (OSRAM) |
| WO (1) | WO2016083499A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015016564A (es) | 2013-06-20 | 2016-04-15 | Novo Nordisk As | Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos. |
| US10392428B2 (en) | 2014-12-17 | 2019-08-27 | Novo Nordisk A/S | GLP-1 derivatives and uses thereof |
| KR102508651B1 (ko) | 2015-12-23 | 2023-03-13 | 더 존스 홉킨스 유니버시티 | 신경계 및 신경변성 상태의 요법으로서 장기간 작용하는 glf-1r 작용제 |
| US10946074B2 (en) | 2016-03-03 | 2021-03-16 | Novo Nordisk A/S | GLP-1 derivatives and uses thereof |
| JP7076442B2 (ja) | 2016-11-07 | 2022-05-27 | ノヴォ ノルディスク アー／エス | Ｐｅｇ化合物のｄｃｈｂｓ活性エステル及びその使用 |
| WO2018113340A1 (zh) * | 2016-12-20 | 2018-06-28 | 中国药科大学 | 多肽p11及其用途 |
| CN109248323B (zh) * | 2017-07-14 | 2023-09-08 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
| JP6633777B2 (ja) | 2017-08-24 | 2020-01-22 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１組成物及びその使用 |
| DK3774862T3 (da) | 2018-04-05 | 2022-09-05 | Sun Pharmaceutical Ind Ltd | Nye GLP-1-analoger |
| WO2019201333A1 (zh) * | 2018-04-19 | 2019-10-24 | 杭州先为达生物科技有限公司 | Glp-1衍生物及其治疗用途 |
| WO2019200594A1 (zh) * | 2018-04-19 | 2019-10-24 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
| EP3788063B1 (en) * | 2018-05-04 | 2023-08-09 | Novo Nordisk A/S | Gip derivatives and uses thereof |
| MY206306A (en) * | 2018-10-26 | 2024-12-07 | Novo Nordisk As | Stable semaglutide compositions and uses thereof |
| CN113728013B (zh) | 2020-01-11 | 2022-06-14 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
| KR20230083294A (ko) | 2020-09-30 | 2023-06-09 | 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 | 폴리펩타이드 접합체 및 사용 방법 |
| KR20230120134A (ko) * | 2020-12-16 | 2023-08-16 | 메디뮨 리미티드 | 폴리펩티드 및 이의 용도 |
| TWI850611B (zh) | 2020-12-18 | 2024-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1及澱粉素受體之共促效劑 |
| TW202304500A (zh) * | 2021-04-21 | 2023-02-01 | 瑞士商諾華公司 | 升糖素樣肽化合物 |
| WO2023284822A1 (en) | 2021-07-14 | 2023-01-19 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion polypeptides for metabolic disorders |
| CN115850438B (zh) * | 2021-12-28 | 2023-05-12 | 北京惠之衡生物科技有限公司 | 一种长效glp-1衍生物 |
| CA3252113A1 (en) | 2022-03-30 | 2023-10-05 | Beijing Ql Biopharmaceutical Co., Ltd. | Liquid pharmaceutical compositions of polypeptide conjugates and their methods of use |
| CN117586375B (zh) * | 2024-01-19 | 2024-07-30 | 苏州金顶生物有限公司 | 一种制备司美格鲁肽的方法 |
| CN120081924A (zh) * | 2024-07-11 | 2025-06-03 | 中国药科大学 | Glp-1r受体激动多肽化合物及其用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3149958B2 (ja) | 1996-08-30 | 2001-03-26 | ノボ ノルディスク アクティーゼルスカブ | Ｇｌｐ―１誘導体 |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| AU2610699A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Derivatives of glp-1 analogs |
| EP1956000B1 (en) | 1999-03-17 | 2016-10-05 | Novo Nordisk A/S | Acylating agents useful for acylating peptides |
| EP1239871A1 (en) | 1999-11-12 | 2002-09-18 | Novo Nordisk A/S | Use of glp-1 agonists for the inhibition of beta cell degeneration |
| GB0020551D0 (en) | 2000-08-22 | 2000-10-11 | Birkett David | Sprinkler system |
| CA2468700A1 (en) | 2002-01-08 | 2003-07-17 | Eli Lilly And Company | Extended glucagon-like peptide-1 analogs |
| EA009366B1 (ru) | 2003-03-19 | 2007-12-28 | Эли Лилли Энд Компани | Связанные с полиэтиленгликолем соединения гпп-1 |
| TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| CN100444898C (zh) * | 2003-09-19 | 2008-12-24 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
| KR101241862B1 (ko) * | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| US7893017B2 (en) | 2004-10-07 | 2011-02-22 | Novo Nordisk A/S | Protracted GLP-1 compounds |
| WO2006097538A1 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Extended glp-1 compounds |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| KR101011081B1 (ko) | 2005-05-13 | 2011-01-25 | 일라이 릴리 앤드 캄파니 | Ｐｅｇ화된 ｇｌｐ-1 화합물 |
| EP2190460B1 (en) | 2007-09-05 | 2014-12-17 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| WO2010142665A1 (en) | 2009-06-11 | 2010-12-16 | Novo Nordisk A/S | Glp-1 and fgf21 combinations for treatment of diabetes type 2 |
| JP2013514322A (ja) | 2009-12-16 | 2013-04-25 | ノヴォ ノルディスク アー／エス | 修飾されたｎ末端を有するｇｌｐ−１受容体アゴニスト化合物 |
| AU2011231503C1 (en) | 2010-03-26 | 2016-03-03 | Novo Nordisk A/S | Novel glucagon analogues |
| US20130137645A1 (en) | 2010-07-19 | 2013-05-30 | Mary S. Rosendahl | Modified peptides and proteins |
| JP6231386B2 (ja) * | 2010-11-09 | 2017-11-15 | ノヴォ ノルディスク アー／エス | リンカーを有する二重アシル化されたｇｌｐ−１誘導体 |
| JP6086067B2 (ja) * | 2010-12-22 | 2017-03-01 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | Ｇｉｐレセプター活性を示すグルカゴンアナローグ |
| BR112013026195A2 (pt) | 2011-04-12 | 2016-11-29 | Novo Nordisk As | derivados de glp-1 duplamente acilados |
| JP2014520159A (ja) | 2011-06-24 | 2014-08-21 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | Ｇｌｐ−１受容体アゴニストの徐放性製剤による糖尿病の治療方法 |
| CA2849673A1 (en) | 2011-09-23 | 2013-03-28 | Novo Nordisk A/S | Novel glucagon analogues |
| JP6250034B2 (ja) | 2012-05-08 | 2017-12-20 | ノヴォ ノルディスク アー／エス | 二重アシル化されたｇｌｐ−１誘導体 |
| MX2015016564A (es) | 2013-06-20 | 2016-04-15 | Novo Nordisk As | Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos. |
| KR20160029079A (ko) | 2013-07-04 | 2016-03-14 | 노보 노르디스크 에이/에스 | Glp-1 유사 펩티드의 유도체 및 그것의 사용 |
| US10392428B2 (en) | 2014-12-17 | 2019-08-27 | Novo Nordisk A/S | GLP-1 derivatives and uses thereof |
-
2015
- 2015-11-26 CN CN201580063041.8A patent/CN106999602B/zh active Active
- 2015-11-26 EP EP15801781.4A patent/EP3226906B1/en active Active
- 2015-11-26 ES ES15801781T patent/ES2739289T3/es active Active
- 2015-11-26 US US15/531,105 patent/US11572398B2/en active Active
- 2015-11-26 WO PCT/EP2015/077757 patent/WO2016083499A1/en not_active Ceased
- 2015-11-26 JP JP2017528491A patent/JP6730278B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018506507A5 (OSRAM) | ||
| RU2531590C2 (ru) | Аналоги глюкагоноподобного пептида-1 и их применение | |
| JP2014501712A5 (OSRAM) | ||
| KR102505628B1 (ko) | 글루카곤 및 glp-1 수용체의 장기-작용성 공-효능제 | |
| JP2013543853A5 (OSRAM) | ||
| RU2013148921A (ru) | Дважды ацилированные производные glp-1 | |
| JP2013517307A5 (OSRAM) | ||
| JP6058646B2 (ja) | 多置換インスリン | |
| JP2015517477A5 (OSRAM) | ||
| JP2015517478A5 (OSRAM) | ||
| JP2018505859A5 (OSRAM) | ||
| JP2014529629A5 (OSRAM) | ||
| JP2016529253A5 (OSRAM) | ||
| WO2011080102A3 (en) | Glp-1 analogues and derivatives | |
| JP2016523241A5 (OSRAM) | ||
| JP2016138127A (ja) | 心臓病の処置 | |
| EP2729493A1 (en) | Novel compounds and their effects on feeding behaviour | |
| JP2016526012A5 (OSRAM) | ||
| JP2016523243A5 (OSRAM) | ||
| JP2014510739A5 (OSRAM) | ||
| JP2013530974A5 (OSRAM) | ||
| JP2015513544A5 (OSRAM) | ||
| EP3113790A1 (en) | Peptides hormone analogues derivable from preproglucagon | |
| CA3073011A1 (en) | Acylated oxyntomodulin peptide analog | |
| CN116171283A (zh) | Glp-1受体拮抗剂 |